Impact of Guidelines on Clinical Practice Intravenous Heparin Use for Acute Ischemic Stroke
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chung, Jong-Won | - |
dc.contributor.author | Kim, Beom Joon | - |
dc.contributor.author | Han, Moon-Ku | - |
dc.contributor.author | Ko, Youngchai | - |
dc.contributor.author | Lee, SooJoo | - |
dc.contributor.author | Kang, Kyusik | - |
dc.contributor.author | Park, Jong-Moo | - |
dc.contributor.author | Park, Sang-Soon | - |
dc.contributor.author | Park, Tai Hwan | - |
dc.contributor.author | Cho, Yong-Jin | - |
dc.contributor.author | Hong, Keun-Sik | - |
dc.contributor.author | Lee, Kyung Bok | - |
dc.contributor.author | Lee, Jun | - |
dc.contributor.author | Ryu, Wi-Sun | - |
dc.contributor.author | Kim, Dong-Eog | - |
dc.contributor.author | Nah, Hyun-Wook | - |
dc.contributor.author | Kim, Dae-Hyun | - |
dc.contributor.author | Cha, Jae-Kwan | - |
dc.contributor.author | Kim, Joon-Tae | - |
dc.contributor.author | Cho, Ki-Hyun | - |
dc.contributor.author | Choi, Jay Chol | - |
dc.contributor.author | Oh, Mi-Sun | - |
dc.contributor.author | Yu, Kyung-Ho | - |
dc.contributor.author | Lee, Byung-Chul | - |
dc.contributor.author | Jang, Myung Suk | - |
dc.contributor.author | Lee, Ji Sung | - |
dc.contributor.author | Lee, Juneyoung | - |
dc.contributor.author | Gorelick, Philip B. | - |
dc.contributor.author | Yoon, Byung-Woo | - |
dc.contributor.author | Bae, Hee-Joon | - |
dc.date.accessioned | 2021-09-03T23:23:12Z | - |
dc.date.available | 2021-09-03T23:23:12Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-06 | - |
dc.identifier.issn | 0039-2499 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/88503 | - |
dc.description.abstract | Background and Purpose-Since its introduction, controversy has existed about the administration of intravenous heparin for the treatment of acute ischemic stroke. We studied trends in the intravenous heparin use during a 6-year time period and the potential influence of clinical guidelines in national language on intravenous heparin administration in Korea. Methods-On the basis of a prospective nationwide multicenter stroke registry, we collected data on patients with acute ischemic stroke who arrived within 7 days of symptom onset during the time period 2008 to 2013. We studied patient demographics, prestroke medical history, stroke characteristics, and stroke treatment. Data from a total of 23 425 patients from 12 university hospitals or regional stroke centers were analyzed. Results-The administration of intravenous heparin steadily decreased throughout the study period: 9.7% in 2008, 10.9% in 2009, 9.4% in 2010, 6.0% in 2011, 4.7% in 2012, and 4.3% in 2013 (P for trend < 0.001). The reduced intravenous heparin use was associated with moderate stroke severity, atrial fibrillation, and stroke of cardioembolic, other-, and undetermined etiology. In a multivariable logistic model, increase of 1 calendar year (odds ratio, 0.89; 95% confidence interval, 0.84-0.95; P < 0.001) and release of clinical practice guidelines in Korean (odd ratio, 0.74; 95% confidence interval, 0.59-0.91; P < 0.01) were independent factors associated with reduction in the frequency of intravenous heparin use. Conclusions-Use of intravenous heparin for acute ischemic stroke treatment has decreased in Korea, and this change may be attributable to the spread and successful implementation of regional clinical practice guidelines. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.subject | MOLECULAR-WEIGHT HEPARIN | - |
dc.subject | QUALITY-OF-CARE | - |
dc.subject | ATRIAL-FIBRILLATION | - |
dc.subject | EARLY MANAGEMENT | - |
dc.subject | REGISTRY | - |
dc.subject | RISK | - |
dc.subject | LANGUAGE | - |
dc.subject | OUTCOMES | - |
dc.subject | DISEASE | - |
dc.subject | ASPIRIN | - |
dc.title | Impact of Guidelines on Clinical Practice Intravenous Heparin Use for Acute Ischemic Stroke | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Juneyoung | - |
dc.identifier.doi | 10.1161/STROKEAHA.116.012639 | - |
dc.identifier.scopusid | 2-s2.0-84966644091 | - |
dc.identifier.wosid | 000377040800034 | - |
dc.identifier.bibliographicCitation | STROKE, v.47, no.6, pp.1577 - U422 | - |
dc.relation.isPartOf | STROKE | - |
dc.citation.title | STROKE | - |
dc.citation.volume | 47 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1577 | - |
dc.citation.endPage | U422 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.subject.keywordPlus | MOLECULAR-WEIGHT HEPARIN | - |
dc.subject.keywordPlus | QUALITY-OF-CARE | - |
dc.subject.keywordPlus | ATRIAL-FIBRILLATION | - |
dc.subject.keywordPlus | EARLY MANAGEMENT | - |
dc.subject.keywordPlus | REGISTRY | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | LANGUAGE | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | ASPIRIN | - |
dc.subject.keywordAuthor | cerebral infarction | - |
dc.subject.keywordAuthor | guideline adherence | - |
dc.subject.keywordAuthor | heparin | - |
dc.subject.keywordAuthor | stroke | - |
dc.subject.keywordAuthor | trends | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.